Search results for: Maria Lowe
Filter search results
Progression-free Survival as a Surrogate Outcome for Overall Survival in Oncology
4 September 2018
…treatment, and for some observations, the drug used in the control arm may also be changed. There is thus a trade-off between the lower random error from increasing the number…
Approaches, Challenges and Successful Stories of Multi-indication Pricing in Europe
28 November 2018
…competition, which in turn has a lowering effect on the level of prices. Payers are also concerned about the complexity of MIP and the resources (e.g. staff from the department…
Is Rate Of Return Pricing A Useful Approach When Value-Based Pricing Is Not Appropriate?
22 March 2019
…for RoR pricing in situations where the value-based price is considered to be inappropriate. The RoR price could be higher or lower than the value-based price, depending on the particular…
Assessing the Life-cycle Value of Second-generation Antipsychotics in Sweden and the UK
17 July 2019
…accrue from lower prices when the product goes off-patent, or whilst still on-patent, when new competitors of the same class enter the market. The present work aims to assess…
Unrelieved Pain in Palliative Care in England
2 September 2019
…know from the VOICES data that reported levels of unrelieved pain are significantly lower in hospices than in other care settings, including hospitals. Our estimate of 5,298 patients who would…
Anchoring Latent Scale Values for the EQ-5D-Y at 0 = Dead
20 January 2020
…both EQ-5D-3L health states from an adult perspective (considering their own health) and EQ-5D-Y health states from a child perspective (considering the health of a 10-year-old child). Overall, respondents gave lower values under…
Are Cost-Effectiveness Thresholds Fit for Purpose for Real-World Decision Making on Access to and Pricing of Pharmaceuticals? A New OHE Paper on Current Methods and Practices, and a Novel Approach for Optimal Thresholds
3 March 2020
…price leads to an Incremental Cost-Effectiveness Ratio lower than the supply-side CET, and a share of the developers’ profits is captured by the health system. Thus, the maximum acceptable CET…
Financing and Scaling Innovation for the COVID Fight: A Closer Look at Demand-Side Incentives for a Vaccine
1 April 2020
…innovators to get an appropriate return on investment, with much lower prices applying after that point, while also ensuring that vaccines are available at manufacturing cost for LICs. The CGD…
Indication-Based Pricing: Are We All Onboard?
12 May 2020
…via IBP would put pressure on payer budgets, although a subset believed that in the long run IBP will generate competition and lead to lower prices. There was a wide…